Patents by Inventor Inger Sandlie

Inger Sandlie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ALBUMIN VARIANTS
    Publication number: 20180162925
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: January 12, 2018
    Publication date: June 14, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20180105577
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20180105578
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20180105576
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20180072792
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 15, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Modified Antibody
    Publication number: 20180030155
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Applicant: Vaccibody AS
    Inventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
  • Modified antibody
    Patent number: 9796787
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: October 24, 2017
    Assignee: Vaccibody A/S
    Inventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
  • MULTIVALENT PHAGE DISPLAY SYSTEMS AND METHODS
    Publication number: 20170211060
    Abstract: The present invention relates to vectors, methods and systems for polypeptide display and selection. Specifically, the present invention relates to vectors, methods, and systems for multivalent phage display using pIX protein of filamentous phage and helper phage.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 27, 2017
    Inventors: Geir Age Loset, Inger Sandlie
  • ANTI-CD14 ANTIBODIES AND USES THEREOF
    Publication number: 20170107294
    Abstract: The present invention relates to chimeric anti-CD14 antibodies and methods of using the same. In some embodiments, the present invention relates to the use of chimieric anti-CD 14 antibodies in research, diagnostic, and therapeutic applications. In one embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 1 and a variable heavy chain of SEQ ID NO: 2 (isolated from the hybridoma clone 18D11). In another embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 3 and a variable heavy chain of SEQ ID NO: 4 (isolated from the hybridoma clone Mil2).
    Type: Application
    Filed: March 21, 2014
    Publication date: April 20, 2017
    Inventors: Terje Espevik, Tom Eirik Mollnes, Inger Sandlie, Corinna Lau, Kristin S. Gunnarsen
  • Multivalent phage display systems and methods
    Patent number: 9598692
    Abstract: The present invention relates to vectors, methods and systems for polypeptide display and selection. Specifically, the present invention relates to vectors, methods, and systems for multivalent phage display using pIX protein of filamentous phage and helper phage.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 21, 2017
    Assignee: University of Oslo
    Inventors: Geir Age Loset, Inger Sandlie
  • ALBUMIN VARIANTS AND USES THEREOF
    Publication number: 20160280763
    Abstract: The present invention relates to albumin variants with an improved affinity for the neonatal Fc receptor (FcRn) and uses thereof, and in particular to the use of such albumin variants as carriers for immunogens. In some embodiments, the present invention relates to vaccines (e.g., vaccines for mucosal delivery) comprising albumin/immunogen fusion proteins.
    Type: Application
    Filed: October 31, 2014
    Publication date: September 29, 2016
    Inventors: Jan Terje Andersen, Inger Sandlie, Malin Bern
  • ALBUMIN VARIANTS
    Publication number: 20160075762
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 17, 2016
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20160075758
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 17, 2016
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20160075756
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 17, 2016
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20160075759
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 17, 2016
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20160075760
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 17, 2016
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20160075761
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 17, 2016
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20160075763
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 17, 2016
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • ALBUMIN VARIANTS
    Publication number: 20160075757
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 17, 2016
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Modified Antibody
    Publication number: 20160039946
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Application
    Filed: October 1, 2015
    Publication date: February 11, 2016
    Inventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE